Endothelin-1-mediated Drug Resistance in EGFR-mutant NSCLC

Progression on therapy in NSCLC is often evaluated radiographically; however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR prom...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Pulido, Inés, Ollosi, Stephen, Aparisi, Salvador, Becker, Jeffrey H., Aliena-Valero, Alicia, Benet, Marta, Rodríguez, María L., López, Adrián, Tamayo-Torres, Eva, Chuliá-Peris, Lourdes, García-Cañaveras, Juan Carlos, Soucheray, Margaret, Dalheim, Annika V., Salom, Juan B., Qiu, Wei, Kaja, Simon, Fernández-Coronado, Javier Alcácer, Alandes, Sandra, Alcácer, Javier, Al-Shahrour, Fátima, Borgia, Jeffrey A., Juan, Oscar, Nishimura, Michael I., Lahoz, Agustín, Carretero, Julián, Shimamura, Takeshi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7541638/
https://ncbi.nlm.nih.gov/pubmed/32747363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-0141
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak